New stock news | The IPO of Meinian Onehealth Healthcare-B (02335) has ended, with the total subscription amount reaching 7.89 billion Hong Kong dollars, oversubscribed 646 times.

Biotechnology company McKo Pharmaceuticals-B (02335) was listed from June 15, 2026 to June 18, 2026, and the latest public offering has ended. According to market news, McKo Pharmaceuticals has obtained a loan of approximately 78.9 billion Hong Kong dollars from brokers for margin financing, with a public offering size of 122 million Hong Kong dollars, oversubscribed by 646 times. McKo Pharmaceuticals plans to globally offer 58.054 million H shares for sale, with 5.8056 million shares offered in Hong Kong (subject to reallocation) and 52.2488 million shares offered internationally (subject to reallocation), with an additional 15% over-allotment option. The offering price per share is expected to be between 18.2 Hong Kong dollars and 21 Hong Kong dollars, with a unit of 200 shares and an entry fee of 4242.4 Hong Kong dollars, raising up to 1.22 billion Hong Kong dollars. The company is expected to be listed for trading on June 24 (Wednesday), with Bank of China International and CMSC International as its joint sponsors. In this IPO, McKo Pharmaceuticals has introduced QYHK Financial, EVEREST MED, and Shun Ming Capital as cornerstone investors, with a total investment of approximately 449 million Hong Kong dollars. The prospectus shows that McKo Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing dual/multi-specific peptide drugs for the treatment of metabolic diseases and cardiovascular diseases. McKo Pharmaceuticals has independently developed a product pipeline consisting of a core product and six other candidate products. The core product MT1013 is a dual-target receptor agonist peptide developed in-house and in phase III, targeting both CaSR and OGP receptors. It is primarily designed for the treatment of secondary hyperparathyroidism (CKD-SHPT) in chronic kidney disease, and has potential for other indications such as mineral and bone metabolism abnormalities in chronic kidney disease with osteoporosis (CKD-MBD) and non-dialysis CKD-SHPT. The company has established four core technology platforms, including (i) dual/multi-specific peptide and peptide-based large molecule technology platforms, (ii) computer-aided peptide design platform, (iii) oral peptide delivery platform, and (iv) drug evaluation platform. These platforms collectively cover the entire research and development process from basic research, drug discovery research, drug development research to new drug application submission, serving as the foundational engine to drive the efficient development of the company's differentiated peptide pipeline. As of the last practicable date, McKo Pharmaceuticals has not obtained market approval for any candidate drugs, nor generated any revenue from product sales. The company expects MT1013 to be commercialized in early 2028 and will implement a dual-track commercialization strategy: through contract sales organizations (CSOs) domestically and through licensing partnerships internationally. Financially, in the fiscal years 2024 and 2025, the company achieved other income of 4.002 million yuan and 2.301 million yuan respectively, while recording annual net losses of approximately 157 million yuan and 185 million yuan. McKo Pharmaceuticals plans to use the net proceeds from the global offering for the following purposes: approximately 39.1% for the ongoing development and planned clinical trials of core products, as well as planned commercial launches; approximately 36.3% for the ongoing development and planned clinical trials of key products, as well as planned commercial launches; approximately 14.6% for the research and development of other candidate products and technology platforms; and approximately 10.0% for working capital and general corporate purposes.